Headlines about HTG Molecular Diagnostics (NASDAQ:HTGM) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.4563084470445 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern’s scoring:
- China Biologic Products Holdings, Inc. (CBPO) noted a price change … – Stocks Gallery (stocksgallery.com)
- Astute Investors Are Taking a Second Look at HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) – FLBC News (flbcnews.com)
- HTG Molecular Diagnostics Inc (HTGM) Sees The Tape Move Mid-Market – Evergreen Caller (evergreencaller.com)
- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Upgraded to Sell at ValuEngine (bulhufas.com)
A number of analysts have recently issued reports on HTGM shares. HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics and gave the company a “buy” rating in a report on Wednesday, August 9th. Rodman & Renshaw increased their price objective on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, May 16th. Zacks Investment Research upgraded HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Thursday, May 11th. Finally, ValuEngine upgraded HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. HTG Molecular Diagnostics presently has an average rating of “Hold” and a consensus price target of $5.75.
Shares of HTG Molecular Diagnostics (NASDAQ HTGM) traded down 2.34% during mid-day trading on Friday, hitting $2.09. The company had a trading volume of 150,426 shares. HTG Molecular Diagnostics has a one year low of $1.20 and a one year high of $13.25. The company’s market capitalization is $23.93 million. The firm’s 50-day moving average price is $2.34 and its 200 day moving average price is $3.37.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. The firm had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $1.80 million. Analysts predict that HTG Molecular Diagnostics will post ($2.28) earnings per share for the current fiscal year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.